The COVID-19 pandemic seems to be fading away from our daily life, but the threat of a recurring circulation of new variants still haunts. While the vaccines continue being developed for a preventive purpose, the neutralizing antibodies stand in the last line of defense as a therapeutic tool. In the latest publication on “Nature Communications”, exciting findings were reported by a collaborative team led by Dr. Che Ma in the Genomics Research Center and Dr. Kuan-Ying Huang in the National Taiwan University Hospital. From the locally recruited individuals in Taiwan, they identified a panel of eight monoclonal antibodies that are all targeting a cryptic yet conserved epitope of the receptor binding domain (RBD) of the surface Spike protein of SARS-CoV-2.


Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2